255 related articles for article (PubMed ID: 11394506)
1. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
Treon SP; Agus TB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
J Immunother; 2001; 24(3):272-9. PubMed ID: 11394506
[TBL] [Abstract][Full Text] [Related]
2. Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.
Treon SP; Shima Y; Preffer FI; Doss DS; Ellman L; Schlossman RL; Grossbard ML; Belch AR; Pilarski LM; Anderson KC
Semin Oncol; 1999 Oct; 26(5 Suppl 14):97-106. PubMed ID: 10561024
[TBL] [Abstract][Full Text] [Related]
3. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC
J Immunother; 2001; 24(3):263-71. PubMed ID: 11394505
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapeutic strategies for the treatment of plasma cell malignancies.
Treon SP; Raje N; Anderson KC
Semin Oncol; 2000 Oct; 27(5):598-613. PubMed ID: 11049026
[TBL] [Abstract][Full Text] [Related]
5. Waldenström's macroglobulinemia: a clinicopathologic study of 22 cases.
Andriko JA; Aguilera NS; Chu WS; Nandedkar MA; Cotelingam JD
Cancer; 1997 Nov; 80(10):1926-35. PubMed ID: 9366295
[TBL] [Abstract][Full Text] [Related]
6. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders.
Treon SP; Anderson KC
Semin Oncol; 2000 Dec; 27(6 Suppl 12):79-85. PubMed ID: 11226004
[TBL] [Abstract][Full Text] [Related]
7. Induction of complete haematological remission after monotherapy with anti-CD20 monoclonal antibody (RITUXIMAB) in a patient with alkylating agent resistant Waldenström's macroglobulinaemia.
Weide R; Heymanns J; Köppler H
Leuk Lymphoma; 1999 Dec; 36(1-2):203-6. PubMed ID: 10613467
[TBL] [Abstract][Full Text] [Related]
8. IgM monoclonal gammopathy/Waldenström's macroglobulinemia: a morphological and immunophenotypic study of the bone marrow.
Feiner HD; Rizk CC; Finfer MD; Bannan M; Gottesman SR; Chuba JV; Amorosi E
Mod Pathol; 1990 May; 3(3):348-56. PubMed ID: 2114024
[TBL] [Abstract][Full Text] [Related]
9. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients.
Milpied N; Vasseur B; Parquet N; Garnier JL; Antoine C; Quartier P; Carret AS; Bouscary D; Faye A; Bourbigot B; Reguerre Y; Stoppa AM; Bourquard P; Hurault de Ligny B; Dubief F; Mathieu-Boue A; Leblond V
Ann Oncol; 2000; 11 Suppl 1():113-6. PubMed ID: 10707791
[TBL] [Abstract][Full Text] [Related]
10. A review of Waldenstrom's macroglobulinemia.
McDermott MK; Bell EM
Clin J Oncol Nurs; 1999 Jul; 3(3):107-11. PubMed ID: 10690041
[TBL] [Abstract][Full Text] [Related]
11. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.
Treon SP; Ioakimidis L; Soumerai JD; Patterson CJ; Sheehy P; Nelson M; Willen M; Matous J; Mattern J; Diener JG; Keogh GP; Myers TJ; Boral A; Birner A; Esseltine DL; Ghobrial IM
J Clin Oncol; 2009 Aug; 27(23):3830-5. PubMed ID: 19506160
[TBL] [Abstract][Full Text] [Related]
12. Macroglobulinemia and chronic B-cell type lymphocytic leukemia in japan--study of autopsy cases.
Kikuchi M; Mitsui T; Takeshita M; Okamura H
Jpn J Clin Oncol; 1983 Sep; 13(3):607-22. PubMed ID: 6417377
[TBL] [Abstract][Full Text] [Related]
13. 2-Chlorodeoxyadenosine treatment of Waldenström's macroglobulinemia--the analysis of own experience and the review of literature.
Lewandowski K; Zaucha JM; Bieniaszewska M; Hałaburda K; Hellmann A
Med Sci Monit; 2000; 6(4):740-5. PubMed ID: 11208402
[TBL] [Abstract][Full Text] [Related]
14. Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity.
Byrd JC; White CA; Link B; Lucas MS; Velasquez WS; Rosenberg J; Grillo-López AJ
Ann Oncol; 1999 Dec; 10(12):1525-7. PubMed ID: 10643548
[TBL] [Abstract][Full Text] [Related]
15. Waldenström's macroglobulinemia: review of 45 cases.
Krajny M; Pruzanski W
Can Med Assoc J; 1976 May; 114(10):899-900, 902, 905. PubMed ID: 817791
[TBL] [Abstract][Full Text] [Related]
16. [Rearrangements of immunoglobulin heavy chain gene in Waldenstr"om's macroglobulinemia].
Matsuda I; Ishiyama T; Hisatake J; Koike M; Tomoyasu S; Tsuruoka N
Rinsho Ketsueki; 1996 Apr; 37(4):275-9. PubMed ID: 8847796
[TBL] [Abstract][Full Text] [Related]
17. [Hypercalcemia complicating Waldenström's disease: a manifestation of Richter's syndrome].
Casassus P; Vannetzel JM; Tricot G; D'Agay MF; Lortholary P; Desrues J; Pariente P
Ann Med Interne (Paris); 1983; 134(2):130-3. PubMed ID: 6410954
[TBL] [Abstract][Full Text] [Related]
18. Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. Groupe Coopératif Macroglobulinémie.
Leblond V; Ben-Othman T; Deconinck E; Taksin AL; Harousseau JL; Delgado MA; Delmer A; Maloisel F; Mariette X; Morel P; Clauvel JP; Duboisset P; Entezam S; Hermine O; Merlet M; Yakoub-Agha I; Guibon O; Caspard H; Fort N
J Clin Oncol; 1998 Jun; 16(6):2060-4. PubMed ID: 9626204
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of therapeutic procedure for Waldenström's macroglobulinemia with hyperviscosity syndrome.
Ito K; Kawasaki T; Hirano K; Sekiguchi N
Ther Apher Dial; 2024 Jun; 28(3):417-423. PubMed ID: 38069574
[TBL] [Abstract][Full Text] [Related]
20. [Waldenström's macroglobulinemia with preserved antierythrocyte and antilipoprotein antibody activity].
Zittoun R; Beaumont JL; Homberg JC; Carbonniere C; Debre P; Bousser J
Sem Hop; 1975 Dec; 51(48):2943-8. PubMed ID: 175506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
